docetaxel + cisplatin (f10a66)

Arm A refers to the control group in a Phase II clinical trial (NCT01069081) conducted by Fudan University, which evaluates the combination of docetaxel and cisplatin for the treatment of metastatic breast cancer. Docetaxel is a taxane small molecule that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to cell cycle arrest in the G2/M phase. Cisplatin is a platinum-based chemotherapeutic agent that forms covalent bonds with DNA bases, creating intra-strand and inter-strand cross-links that interfere with DNA replication and transcription, ultimately triggering apoptosis. This trial arm serves as the standard-of-care comparator to assess whether the addition of high-dose esomeprazole can enhance the efficacy of this chemotherapy regimen by modulating the acidic tumor microenvironment.

Other names

docetaxel and cisplatindocetaxel plus cisplatinArm A-Fudan University-breast cancer (metastatic)